Free Trial

Mineralys Therapeutics (NASDAQ:MLYS) Shares Down 6.2% - What's Next?

Mineralys Therapeutics logo with Medical background

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report)'s stock price dropped 6.2% during trading on Monday . The company traded as low as $13.44 and last traded at $13.64. Approximately 116,483 shares changed hands during trading, a decline of 87% from the average daily volume of 901,379 shares. The stock had previously closed at $14.54.

Analysts Set New Price Targets

MLYS has been the topic of a number of recent research reports. HC Wainwright reaffirmed a "buy" rating and set a $42.00 price target on shares of Mineralys Therapeutics in a research report on Tuesday, June 17th. Guggenheim set a $48.00 price target on shares of Mineralys Therapeutics and gave the stock a "buy" rating in a research report on Wednesday, May 14th. Wall Street Zen lowered shares of Mineralys Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, June 14th. Finally, Jefferies Financial Group initiated coverage on shares of Mineralys Therapeutics in a research report on Tuesday, June 10th. They set a "hold" rating and a $15.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $32.25.

Read Our Latest Report on MLYS

Mineralys Therapeutics Stock Performance

The stock's fifty day moving average price is $14.94 and its two-hundred day moving average price is $12.98. The company has a market cap of $881.89 million, a P/E ratio of -3.63 and a beta of -0.30.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.79) earnings per share for the quarter, topping analysts' consensus estimates of ($1.02) by $0.23. On average, equities research analysts forecast that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current year.

Insider Transactions at Mineralys Therapeutics

In other news, insider David Malcom Rodman sold 11,366 shares of the company's stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $15.29, for a total transaction of $173,786.14. Following the completion of the sale, the insider owned 106,669 shares of the company's stock, valued at approximately $1,630,969.01. This represents a 9.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Jon Congleton sold 15,319 shares of the company's stock in a transaction that occurred on Friday, April 11th. The stock was sold at an average price of $12.19, for a total transaction of $186,738.61. Following the transaction, the chief executive officer owned 862,289 shares of the company's stock, valued at approximately $10,511,302.91. This represents a 1.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 48,808 shares of company stock valued at $655,402. Company insiders own 33.24% of the company's stock.

Hedge Funds Weigh In On Mineralys Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. increased its position in Mineralys Therapeutics by 166.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 298,395 shares of the company's stock worth $4,739,000 after purchasing an additional 186,480 shares in the last quarter. Swedbank AB acquired a new position in Mineralys Therapeutics during the 1st quarter worth approximately $5,204,000. Voya Investment Management LLC acquired a new position in Mineralys Therapeutics during the 1st quarter worth approximately $255,000. Strs Ohio acquired a new position in Mineralys Therapeutics during the 1st quarter worth approximately $359,000. Finally, Woodline Partners LP acquired a new position in Mineralys Therapeutics during the 1st quarter worth approximately $757,000. 84.46% of the stock is currently owned by institutional investors and hedge funds.

Mineralys Therapeutics Company Profile

(Get Free Report)

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.

Featured Articles

Should You Invest $1,000 in Mineralys Therapeutics Right Now?

Before you consider Mineralys Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mineralys Therapeutics wasn't on the list.

While Mineralys Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines